HDAC9 and synovial sarcoma: As each type of agents is individually effectiveagainst synovial sarcoma cells, and synergy could potentially be of greatbenefit to patients, in this study, we seek to test combinations of 17-AAG withthe HDAC inhibitor MS-275 for efficacy against synovial sarcoma.